法尼基转移酶抑制剂 - Suppr | 超能文献

Farnesyltransferase inhibitors.

作者信息

Adjei A A

机构信息

Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

出版信息

Cancer Chemother Biol Response Modif. 2001;19:149-64.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Farnesyltransferase inhibitors.法尼基转移酶抑制剂

Cancer Chemother Biol Response Modif. 2001;19:149-64.

2

Farnesyltransferase inhibitors.法尼基转移酶抑制剂

Cancer Chemother Biol Response Modif. 2002;20:151-67.

3

Farnesyltransferase inhibitors as anticancer agents: current status.法尼基转移酶抑制剂作为抗癌剂：现状

Curr Opin Investig Drugs. 2003 Dec;4(12):1428-35.

4

Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?法尼基转移酶抑制剂：癌症化疗的合理方法？

J Med Chem. 2004 Apr 8;47(8):1869-78. doi: 10.1021/jm0305467.

5

Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.法尼基转移酶抑制剂：临床前和临床研究结果概述

Cancer Res. 2003 Sep 15;63(18):5656-68.

6

[Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].[法尼基转移酶抑制剂：开发潜在抗癌药物的新方法]

Pharm Unserer Zeit. 1998 Nov;27(6):278-88. doi: 10.1002/pauz.19980270608.

7

Immunohistochemical assays of farnesyltransferase inhibition in patient samples.患者样本中法尼基转移酶抑制作用的免疫组织化学检测

Methods Mol Med. 2003;85:141-5. doi: 10.1385/1-59259-380-1:141.

8

Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.非硫醇法尼基转移酶抑制剂：N-（4-甲苯基乙酰氨基-3-苯甲酰基苯基）-3-芳基呋喃基丙烯酸酰胺

Bioorg Med Chem. 2004 Sep 1;12(17):4585-600. doi: 10.1016/j.bmc.2004.07.010.

9

Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.非硫醇法尼基转移酶抑制剂：基于二苯甲酮的双底物类似物法尼基转移酶抑制剂的法尼基转移酶抑制作用及细胞活性

Arch Pharm (Weinheim). 2003 Jul;336(4-5):242-50. doi: 10.1002/ardp.200300758.

10

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.他汀类药物和法尼基转移酶抑制剂对癌症发生发展的影响。

Cancer Treat Rev. 2004 Nov;30(7):609-41. doi: 10.1016/j.ctrv.2004.06.010.

引用本文的文献

1

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.靶向突变型 KRAS 用于抗癌治疗的新型小分子调节剂的研究进展。

J Med Chem. 2013 Jul 11;56(13):5219-30. doi: 10.1021/jm3017706. Epub 2013 Apr 23.

2

Dapson in heterocyclic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties.杂环化学中的氨苯砜，第八部分：一些带有生物活性1,3 - 二氢吡啶、色烯和色烯并吡啶基团的新型磺酰基双化合物的合成、分子对接及抗癌活性

Chem Cent J. 2012 Jul 2;6(1):64. doi: 10.1186/1752-153X-6-64.